Table 2.
Reported effects of three classes of PLA2 inhibitor against EDHF-type relaxations
PLA2 isoform | cPLA2 | iPLA2 | sPLA2 | Inhibits EDHF/species and artery type | Reference |
---|---|---|---|---|---|
ONO-RS-082 | + | + | +Rabbit mesenteric | Hutcheson et al. (1999) | |
+Rat coronary | Fulton et al. (1996) | ||||
−Rat mesenteric | Tanaka et al. (1999) | ||||
AACOCF3 | ++ | + | +Rabbit mesenteric | Hutcheson et al. (1999); Hutcheson & Griffith (2000) | |
+Rat coronary, mesenteric, cerebral | Fulton et al. (1996); Adeagbo & Henzel (1998); You et al. (2002) | ||||
−Guinea-pig coronary, carotid −bovine coronary | Yamanaka et al. (1998); Quignard et al. (2002); Drummond et al. (2000) | ||||
PACOCF3 | + | ++ | + | +Rat cerebral | You et al. (2002) |
OOPC | + | +Human subcutaneous | Coats et al. (2001) | ||
+Rat coronary, mesenteric | Fulton et al. (1996); Adeagbo & Henzel (1998) | ||||
HELSS | + | −Rabbit mesenteric | Hutcheson et al. (1999) | ||
−Rat mesenteric, cerebral | Adeagbo & Henzel (1998); You et al. (2002) |
+/− signs reflect the ability of each compound to inhibit different PLA2 isoenzymes and relaxation. cPLA2, cytosolic Ca2+-dependent phospholipase A2; iPLA2, cytosolic Ca2+-independent phospholipase A2; sPLA2, secretory phospholipase A2. ONO-RS-082, 2-(p-amylcinnamoyl) amino-4-chlorobenzoic acid; AACOCF3, arachidonyl trifluoromethyl ketone; PACOCF3, palmitoyl trifluoromethyl ketone; OOPC, oleyloxyethyl phosphorylcholine; HELSS, haloenol lactone suicide substrate.